Clinical trials: SARS-COV 2
Covid19
COVID-19 Seroprevalence Study in ITM Staff
In Belgium, the corona virus disease 2019 (COVID-19) epidemic is in the growing phase of its second wave. The Belgian crisis cell is balancing between allowing the economy to recover and minimize the disease spread.
- Trial name
- CovAb (NCT04503447)
- Where
- Belgium
- Volunteers
- 330 people
- Sponsor
- Institute of Tropical Medicine, Belgium
COVID, SARS-CoV 2
Characteristics of Patients With COVID-19 in Meta State, Colombia
This observational study aims to collect detailed clinical information on confirmed or suspected patients of COVID-19 treated in hospitals from Meta State, Colombia. The objectives are: 1.
- Conditions
- COVID, SARS-CoV 2, SARS Pneumonia, SARS (Disease)
- Trial name
- NCT04456426
- Sponsor
- Hospital Departamental de Villavicencio
Respiratory Distress Syndrome
The ECOVITA Study - Validation of LUS Score in SARS-CoV-2 Disease, i.e COVID-19
Lung Ultrasound (LUS) has been revealing an extremely useful tool to identify and monitor complications from Sars-COV-2 disease.
- Trial name
- ECOVITA (NCT04871685)
- Testing
- lung ultrasound
- Where
- Italy
- Volunteers
- 950 people
- Sponsor
- University of Campania Luigi Vanvitelli
Acute Respiratory Distress Syndrom (SARS-Cov 2)
Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection
Sarcopenia is a risk factor for adverse outcome in critically ill patients. Sarcopenia might be estimated from muscle surface measure on tomodensitometry.
- Trial name
- MUSCOV (NCT05594550)
- Testing
- Data collection, analysis of thoracic scans
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
COVID, COVID-19
Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19
Facing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro…
- Conditions
- COVID, COVID-19, SARS-CoV 2, Coronavirus
- Trial name
- NCT04420247
- Testing
- Chloroquine, Hydroxychloroquine, standard care
- Where
- Brazil
- Volunteers
- 142 people
- Sponsor
- Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva
SARS-CoV 2, COVID-19
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could…
- Trial name
- NCT04383587
- Testing
- Serologic testing
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
COVID-19, SARS CoV 2 Infection
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
The purpose of this study is to describe the long-term health effects of COVID-19 in a population of mostly Black and Latinx individuals and their households who were diagnosed with COVID-19 at Columbia University Irving Medical…
- Trial name
- NCT05467930
- Testing
- Survey, Medical History Review, Sample Collection
- Where
- United States
- Volunteers
- 1,520 people, healthy volunteers welcome
- Sponsor
- Columbia University
COVID-19, Coronavirus Infection
Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)
Randomized, double-blind prospective trial to test the efficacy of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65…
- Conditions
- COVID-19, Coronavirus Infection, SARS CoV 2 Infection
- Trial name
- MOR2 (NCT05178173)
- Testing
- 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
COVID-19, SARS-CoV 2
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort
DESIGN Longitudinal prospective observational multicentre study. Primary objective: Understand the immune mechanisms driving COVID-19 disease in patients with a history of lung disease
- Conditions
- COVID-19, SARS-CoV 2, ARDS, Human, Immune System Disorder
- Trial name
- PROSAIC-19 (NCT04444609)
- Testing
- Blood tests sputum, nasal lavage and brushing
- Where
- United Kingdom
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Imperial College London
SARS-CoV Infection
Diode Laser 940 nm in Management of Loss of Taste Sensation
The global pandemic has recently emerged by transmission of SARS-CoV2 virus. The virus has had a massive impact on health, wealth and social aspects worldwide.
- Trial name
- NCT04821999
- Testing
- a 940-nm diode laser
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Fayoum University
Covid19
Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs
This study is about the current knowledge on the immunological changes observed in various healthcare workers in this part of the world, who remained asymptomatic while working in high exposure areas of COVID-19 infection.
- Trial name
- NCT04563247
- Testing
- IgG SARS CoV 2 antibodies
- Where
- Pakistan
- Volunteers
- 970 people
- Sponsor
- Lahore General Hospital
SARS CoV 2 Infection
Rutgers Pilot for PREDICT- Patient POC Test
A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral antigen using a point-of-care (POC) Rapid…
- Trial name
- NCT05612724
- Testing
- Testing for SARS CoV2 Antigen
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Maternal Fetal Infection Transmission, COVID-19
Maternal-foetal Transmission of SARS-Cov-2
One case of maternal-fetal transmission of SARS Cov-2 was published (1). Ig M and Ig G were found at two hours after birth of a new born from a mother COVID-19.
- Conditions
- Maternal Fetal Infection Transmission, COVID-19, SARS-CoV 2
- Trial name
- TMF-COVID-19 (NCT04395924)
- Testing
- Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Reproductive Disorder, Neurodegeneration
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome.
- Conditions
- Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID
- Trial name
- NCT07224490
- Testing
- Kisspeptin 112-121
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stephanie B. Seminara, MD
COVID 19, SARS-CoV 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Trial name
- NCT04399980
- Testing
- Mavrilimumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- The Cleveland Clinic
COVID-19, Vaccine Reaction
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Phase II, non-randomized, open-label, comparative, national, multicenter trial in Mali, aimed to assess the humoral vaccine immune response induced by Ad26.COV2.S vaccine in 200 adults one month after receiving the complete…
- Conditions
- COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
- Trial name
- CoviComMali (NCT05409261)
- Testing
- Ad26.COV2.S
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
SARS-CoV 2, Viral Infection
Anti-SARS Cov-2 T Cell Infusions for COVID 19
This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high…
- Conditions
- SARS-CoV 2, Viral Infection, COVID 19
- Trial name
- BATIT (NCT04401410)
- Testing
- Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Convalescent Plasma, COVID-19
Efficacy and Safety of COVID-19 Convalescent Plasma
Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
- Conditions
- Convalescent Plasma, COVID-19, SARS-CoV 2
- Trial name
- NCT04397523
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- North Macedonia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute for Transfusion Medicine of RNM
COVID-19, SARS-CoV 2
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by…
- Conditions
- COVID-19, SARS-CoV 2, Respiratory Disease, Pneumonia, Viral
- Trial name
- NCT04456088
- Testing
- 150 ppm Nitric Oxide delivered through LungFit Delivery System, 80 ppm Nitric Oxide delivered through LungFit Delivery System
- Sponsor
- Beyond Air Inc.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection), Hospitalized Patients
Antibodies Responses to COVID-19 Infection in Hospitalized Patients
1.5. Why this clinical study? The prevalence of seropositivity following SARS-CoV 2 infection might have its own potential benefits in terms of predicting the end of pandemic and the validity of herd immunity.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection), Hospitalized Patients, Laboratory-confirmed SARS-CoV 2 Infection
- Trial name
- No-SARS (NCT04520880)
- Testing
- Testing procedure for Binding antibodies, Neutralizing antibodies
- Where
- Saudi Arabia
- Volunteers
- 158 people
- Sponsor
- Imam Abdulrahman Bin Faisal University